Ipamorelin vs tesamorelin vs sermorelin compared

Last updated 2026-07-24

What is the basic difference between ipamorelin, tesamorelin, and sermorelin?

All three are peptides that push your pituitary gland to release more growth hormone, but they don't do it the same way. Sermorelin and tesamorelin are both growth-hormone-releasing hormone (GHRH) analogs. They mimic your body's natural GHRH and bind to the GHRH receptor on pituitary cells, telling them to make and release growth hormone in a pulse ^[1]. Ipamorelin works through a completely different receptor. It's a ghrelin-receptor agonist, sometimes called a growth hormone secretagogue or GHRP (growth hormone releasing peptide). Instead of mimicking GHRH, it mimics ghrelin, the "hunger hormone," and binds to the GHS-R1a receptor to trigger GH release through a separate pathway ^[2]. This matters practically. GHRH analogs (sermorelin, tesamorelin) tend to preserve the body's natural pulsatile GH pattern and have a built-in ceiling, because the pituitary still needs enough GHRH receptor sensitivity and somatostatin has to allow the pulse through. Ghrelin-mimetics like ipamorelin bypass some of that regulation and are often described as more potent per dose, though "potent" doesn't mean better tolerated or better studied. Combination protocols (a GHRH analog plus a GHRP) are common in anti-aging and bodybuilding circles specifically because the two mechanisms are additive, but that combination has essentially no formal clinical trial data behind it as a mixture. For a full breakdown of what sermorelin does on its own, see our sermorelin overview.

What is each peptide actually FDA-approved to treat?

This is the single biggest practical difference, and it's the one people skip past. Only tesamorelin currently has FDA approval, and it's for one narrow indication: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It's sold under the brand name Egrifta (and the newer Egrifta SV formulation) ^[3]. Sermorelin has FDA history but no current active approval. It was approved in the 1990s under the brand name Geref, for diagnostic testing of pituitary GH function and for treating certain cases of GH deficiency in children. Geref was discontinued by the manufacturer for business reasons, not pulled for safety problems. FDA's Drugs@FDA database lists Geref (NDA 019667) as discontinued, a different category from a safety-driven withdrawal ^[4]. That distinction matters: a lot of peptides on the market never had an approval to lose. Sermorelin actually went through NDA review once, which is a real regulatory pedigree most compounded peptides simply don't have. Ipamorelin has never been FDA-approved for anything, in humans, at any dose. It exists in the U.S. market almost entirely as a "research chemical" sold with a disclaimer that it's not for human consumption, which is a legal fiction some clinics work around by having a prescriber write for it through a compounding pharmacy. There is no FDA-reviewed safety or efficacy file on ipamorelin the way there is on tesamorelin or on Geref-era sermorelin. Here's the approval picture side by side:

How do the three peptides compare on dosing?

Dosing protocols differ because the peptides have different half-lives and different clinical traditions behind them. Sermorelin is typically dosed at 200 to 300 mcg per day, injected subcutaneously at night to mimic the body's natural nocturnal GH pulse. Some protocols use up to 500 mcg, but higher isn't automatically better since the pituitary response has a ceiling. If you want dosing ranges broken down further, our sermorelin dosage chart and sermorelin dosage calculator walk through weight-based and age-based adjustments. Tesamorelin's approved dose, per the Egrifta SV label, is 1 mg injected subcutaneously once daily (the reformulated Egrifta SV lowered the volume needed compared to the original 2 mg Egrifta) ^[3]. That's a fixed dose studied in randomized trials, which is a very different situation from sermorelin or ipamorelin, where "standard" doses come from clinical tradition and compounding pharmacy norms rather than FDA-reviewed trial data. Ipamorelin protocols in clinical practice (off-label, compounded) commonly run 200 to 300 mcg per injection, one to three times daily, sometimes stacked with sermorelin or CJC-1295. There's no FDA label to check this against, so these numbers come from prescriber consensus and compounding pharmacy dosing sheets, not trial data. Be skeptical of anyone quoting these as precise or evidence-backed. A rough sense of typical daily dosing:

How does sermorelin compare to HGH directly?

This is probably the question most readers actually came here with, so let's answer it straight. Sermorelin is not HGH. It's a peptide that stimulates your own pituitary to make more of your own growth hormone. Injectable HGH (somatropin) is the hormone itself, made recombinantly and injected directly. The honest tradeoff: sermorelin produces a milder, more physiologic rise in GH because your pituitary still governs the release, complete with negative feedback from somatostatin. That means less risk of overshoot, but also a real ceiling on how much GH you can get. If your pituitary is damaged or has very few functioning somatotroph cells (as can happen after pituitary surgery, radiation, or in older age with meaningfully reduced pituitary reserve), sermorelin has less to work with and the response is smaller. Recombinant HGH bypasses the pituitary entirely and delivers a known, larger dose regardless of what your gland can still do. For children with confirmed GH deficiency, standard care is recombinant HGH, not sermorelin. Sermorelin's approved role historically was more diagnostic (testing whether the pituitary could respond at all) and as a treatment option in a narrower slice of cases. For adults chasing general wellbeing, body composition, or sleep benefits, sermorelin is the gentler, cheaper, and lower-risk option, but it is also the weaker one if what you actually need is a large, reliable GH increase. Anyone told sermorelin will match HGH's effects milligram for milligram is being sold something the biology doesn't support. See our sermorelin long-term side effects page for what the tolerability difference looks like over months of use.

What does the clinical evidence actually show for each one?

Tesamorelin has the strongest trial base of the three, by a wide margin. Randomized, placebo-controlled phase 3 trials in HIV-associated lipodystrophy showed statistically significant reductions in visceral adipose tissue, which is what drove FDA approval ^[3][5]. That's real, published, peer-reviewed data with defined endpoints. Sermorelin has decades-old trial data, mostly from its diagnostic-testing era and pediatric GH deficiency studies in the 1990s, plus some adult studies on GH-releasing capacity. The evidence is real but old, and much of it is aimed at proving the pituitary can respond, not at proving broad wellness benefits. Endocrine Society guidance on adult GH deficiency discusses GHRH-based stimulation testing but centers treatment recommendations on recombinant GH replacement, not GHRH analog therapy, for confirmed adult GHD ^[6]. Ipamorelin has the thinnest human evidence of the three. Most of what exists is small, early-phase pharmacology studies from decades ago looking at GH secretagogue activity, plus a larger body of animal and in vitro receptor-binding work ^[2]. There is no large randomized controlled trial establishing a clinical indication for ipamorelin in humans. Marketing claims about fat loss, muscle gain, or anti-aging benefits from ipamorelin are running well ahead of what's actually been published.

Which one has the longest half-life and how does that change dosing frequency?

Half-life differences explain a lot of the dosing schedule differences above. Sermorelin has a short half-life, around 11 to 12 minutes in circulation, which is why it's dosed once nightly to catch the natural nocturnal GH pulse rather than dosed to maintain constant blood levels ^[7]. Tesamorelin's half-life is also short, roughly 25 to 30 minutes for the active peptide, but its once-daily dosing schedule in the Egrifta trials was built around consistent daily pituitary stimulation rather than trying to match a specific circadian pulse ^[3]. Ipamorelin's half-life is reported around 2 hours in some pharmacology sources, longer than sermorelin or tesamorelin, which is part of why some multi-dose-per-day protocols exist for it. But because ipamorelin was never taken through FDA-reviewed human pharmacokinetic trials at scale, these numbers come from smaller studies and should be treated as approximate, not label-grade data.

Can you combine ipamorelin, tesamorelin, and sermorelin, and is that a good idea?

Combining a GHRH analog (sermorelin or tesamorelin) with a ghrelin-mimetic (ipamorelin) is common in compounding-pharmacy protocols, on the theory that hitting two different receptors produces a bigger GH pulse than either alone. Mechanistically that's plausible; GHRH analogs and GHRPs do act on separate receptors and some older pharmacology studies show additive effects when combined. What doesn't exist is a large controlled trial testing the actual combination for safety or long-term outcomes in the way tesamorelin was tested alone for lipodystrophy. You're relying on mechanism-based reasoning and prescriber experience, not a completed clinical trial file. That's not automatically wrong, but it's a meaningfully different evidence standard than what got tesamorelin its FDA approval. Combining sermorelin with tesamorelin specifically is unusual since they hit the same receptor; there's little rationale for stacking two GHRH analogs together. The realistic combination people mean is sermorelin (or tesamorelin) plus ipamorelin. If a prescriber recommends this, ask directly what data supports the combination beyond receptor mechanism, and ask what monitoring (IGF-1 levels, glucose, side effect check-ins) they'll do along the way.

What do these peptides cost, and is one much cheaper than the others?

Cost varies a lot depending on whether you're getting a branded, FDA-approved product or a compounded peptide. Egrifta (tesamorelin) is the most expensive by far because it's a branded, patent-protected drug. List prices for a month's supply have historically run into the thousands of dollars without insurance coverage, and insurance typically requires the HIV lipodystrophy diagnosis to cover it at all, since that's the only approved use. Compounded sermorelin and compounded ipamorelin, sourced through a compounding pharmacy with a prescription, tend to run far cheaper, commonly in the range of $150 to $400 per month depending on dose and pharmacy, though this varies widely and isn't insurance-covered since it's off-label or non-approved use. These are compounding-market prices, not FDA-set prices, so shop the specific quote you're given rather than trusting a number you saw somewhere else. Cost alone shouldn't drive the decision. A cheap peptide with thin safety data is not automatically a bargain.

What are the side effects and safety differences between the three?

Tesamorelin's side effect profile is the best documented because it went through FDA trials. Labeled side effects include injection site reactions, joint pain (arthralgia), swelling (edema), and a documented effect of raising blood glucose and reducing insulin sensitivity in some patients, which is specifically flagged in prescribing information for people with diabetes risk ^[3]. Sermorelin's reported side effects, from its trial history and clinical use, are generally mild: injection site redness, flushing, headache, and occasionally dizziness. Because it works through the body's own feedback loop, the risk of GH overshoot is lower than with direct HGH or with high-dose secretagogue stacking. Our sermorelin long-term side effects page covers what's known about extended use specifically. Ipamorelin's side effect profile from small studies and clinical reports includes injection site reactions, headache, and some reports of increased hunger (consistent with its ghrelin-receptor mechanism). Because large controlled human trials don't exist, rare or long-term risks aren't well characterized. That's the honest gap: absence of documented severe side effects isn't the same as proof of safety, it may just mean nobody has looked hard enough yet.

How do you decide which one is right to ask a prescriber about?

Start with what problem you're actually trying to solve, because that alone rules out two of the three most of the time. If you have HIV-associated lipodystrophy with excess abdominal fat, tesamorelin is the one with an actual FDA approval and trial data behind it for that exact problem. That's a straightforward case for asking about Egrifta specifically. If you're an adult with confirmed, tested GH deficiency, the guideline-backed standard of care is recombinant HGH, not any of these three peptides. GHRH analogs like sermorelin have more of a supporting or diagnostic role. If you're an adult without a diagnosed deficiency who is interested in gentle, physiologic GH support with a long regulatory track record (even a discontinued one) and a milder side effect profile, sermorelin is the more conservative and better-documented off-label option of the two non-tesamorelin choices. Ipamorelin, alone or stacked with sermorelin, is the least-studied path of the three; treat marketing claims about it accordingly. Whatever you land on, the honest process is: bloodwork first (IGF-1, and a fuller panel your prescriber wants), a real conversation about goals, and a provider-reviewed prescription rather than an unmonitored self-purchase. Sermorelin Co connects that provider-review process to a licensed pharmacy partner that fulfills the actual prescription, rather than selling raw peptide with no clinical oversight.

Where does sermorelin's Geref history fit into all this?

Geref is worth understanding because it's the thing that separates sermorelin from most other peptides in this comparison, tesamorelin's approval history aside. Geref (sermorelin acetate) received FDA approval and was marketed in the U.S. for diagnostic testing of pituitary GH secretion and for treatment of certain pediatric growth hormone deficiencies ^[4]. The key fact people get wrong: Geref was discontinued for commercial reasons, not because of a safety recall or an FDA-mandated withdrawal. Manufacturers discontinue drugs for all kinds of business reasons, including low sales volume, manufacturing cost, or a company deciding to focus resources elsewhere. FDA's Drugs@FDA record for NDA 019667 treats this as a different category from a safety-driven withdrawal ^[4]. That history means sermorelin isn't a peptide that appeared out of nowhere in a research catalog. It went through an actual New Drug Application review process at some point in its history, which is more regulatory scrutiny than ipamorelin has ever received in the U.S. It doesn't mean today's compounded sermorelin products carry the same FDA oversight as the original Geref did; compounded versions are regulated differently, under state pharmacy boards and, in some cases, FDA's compounding rules for 503A and 503B facilities under sections of the Federal Food, Drug, and Cosmetic Act ^[8]. But the underlying molecule has a real approval history to point to.

Frequently asked questions

Is ipamorelin the same thing as sermorelin?

No. Sermorelin is a GHRH analog that mimics your body's natural growth-hormone-releasing hormone. Ipamorelin is a ghrelin-receptor agonist (a GHRP) that works through a completely different receptor. They're sometimes combined in compounded protocols, but they are chemically and mechanistically distinct peptides, not variations on the same drug.

Which is stronger, ipamorelin or sermorelin?

Ipamorelin is often described as producing a larger GH pulse per dose because it bypasses some of the pituitary's natural feedback regulation, while sermorelin works within that feedback loop. "Stronger" doesn't mean better studied or safer, though; ipamorelin has far less human trial data behind it than sermorelin's historical Geref approval.

Is tesamorelin better than sermorelin?

For its approved use (reducing excess abdominal fat in HIV-associated lipodystrophy), tesamorelin has strong randomized trial data and FDA approval that sermorelin doesn't have for that indication. For general off-label GH support, sermorelin is cheaper, has a milder side effect profile, and has its own separate FDA history through Geref.

Why was sermorelin (Geref) discontinued?

Geref was discontinued by its manufacturer for business reasons, not pulled for a safety problem or FDA-mandated withdrawal. FDA's Drugs@FDA record distinguishes this from a safety withdrawal. Compounded sermorelin is still available today through compounding pharmacies with a prescription, separate from the original discontinued brand.

Can you take sermorelin and ipamorelin together?

Some prescribers combine them because they act on separate receptors (GHRH receptor and ghrelin receptor) and may produce an additive GH pulse. There's no large controlled trial testing this specific combination for safety or outcomes, so it relies on mechanism-based reasoning and prescriber experience rather than completed clinical trial data.

Does insurance cover ipamorelin, tesamorelin, or sermorelin?

Tesamorelin (Egrifta) can be covered by insurance specifically for its FDA-approved HIV-lipodystrophy indication, though prior authorization is common. Sermorelin and ipamorelin are typically prescribed off-label or as compounded, non-approved products, so insurance coverage is uncommon; expect to pay out of pocket.

Is ipamorelin legal to buy in the US?

Ipamorelin has no FDA-approved human use. It's often sold labeled "research use only," which technically means not for human consumption. Some clinics prescribe it off-label through compounding pharmacies, which is a different legal pathway than buying it as an unregulated research chemical online.

How is sermorelin different from HGH directly?

Sermorelin stimulates your own pituitary to release your own growth hormone, producing a milder, feedback-regulated rise. Injectable HGH (somatropin) is the hormone itself, bypassing the pituitary entirely. HGH gives a larger, more predictable increase; sermorelin is gentler but weaker, especially if your pituitary reserve is already limited.

What is tesamorelin actually approved to treat?

Tesamorelin, sold as Egrifta or Egrifta SV, is FDA-approved specifically to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. It is not FDA-approved for general anti-aging use, bodybuilding, or fat loss outside that specific patient population.

Which peptide has the most research behind it?

Tesamorelin has the most rigorous clinical trial data of the three, backed by phase 3 randomized controlled trials that supported its FDA approval. Sermorelin has older but real trial history from its Geref-approval era. Ipamorelin has the thinnest human evidence, mostly small early-phase studies and preclinical work.

Do ipamorelin, tesamorelin, and sermorelin all raise IGF-1 levels?

Yes, all three work by increasing growth hormone release, which in turn raises IGF-1 (insulin-like growth factor 1), the marker prescribers typically monitor with bloodwork. The degree of IGF-1 increase varies by peptide, dose, and individual pituitary response, which is part of why baseline and follow-up labs matter.

Can these peptides be used for weight loss or muscle gain?

Tesamorelin is only approved for reducing visceral fat in HIV lipodystrophy specifically, not general weight loss. Sermorelin and ipamorelin are sometimes used off-label with body composition goals in mind, but neither has FDA approval for weight loss or muscle building, and the supporting evidence for those specific outcomes is limited.

Sources

1. National Cancer Institute, Dictionary of Cancer Terms: growth hormone-releasing hormone: GHRH analogs bind the GHRH receptor to stimulate pituitary GH release
2. Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology, 1998 (PMID 9849822): Ipamorelin acts as a selective ghrelin-receptor (GHS-R1a) agonist, a distinct mechanism from GHRH analogs
3. U.S. Food and Drug Administration, Egrifta SV (tesamorelin for injection) prescribing information, NDA 022550: Tesamorelin (Egrifta SV) is FDA-approved for reduction of excess abdominal fat in HIV-associated lipodystrophy, dosed at 1 mg subcutaneously daily, with labeled risks including glucose intolerance and arthralgia
4. U.S. Food and Drug Administration, Drugs@FDA record for Geref (sermorelin acetate), NDA 019667: Geref (sermorelin acetate) is listed as a discontinued drug product rather than one withdrawn for safety reasons
5. Falutz J, et al. "Effects of tesamorelin on visceral fat and liver fat in HIV patients with abdominal fat accumulation." New England Journal of Medicine, 2007 (PMID 17715410): Randomized placebo-controlled trials showed tesamorelin significantly reduced visceral adipose tissue in HIV-associated lipodystrophy
6. Molitch ME, et al. Endocrine Society Clinical Practice Guideline, "Evaluation and Treatment of Adult Growth Hormone Deficiency," Journal of Clinical Endocrinology & Metabolism, 2011 (PMID 21296991): Guideline-based treatment for confirmed adult GH deficiency centers on recombinant GH replacement rather than GHRH analog therapy
7. Prakash A, Goa KL. "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency." BioDrugs, 1999 (PMID 10547896): Sermorelin has a short plasma half-life of roughly 11-12 minutes, informing its once-nightly dosing schedule
8. 21 U.S.C. 353a and 353b, Federal Food, Drug, and Cosmetic Act sections governing pharmacy compounding (503A) and outsourcing facilities (503B), via U.S. Government Publishing Office: Compounded peptide products are regulated under the FD&C Act's 503A and 503B compounding framework rather than standard NDA approval